Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:BTAI NASDAQ:CNTX NASDAQ:GNTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.82-4.0%$3.06$2.00▼$5.00$17.80M2.257.19 million shs63,597 shsBTAIBioXcel Therapeutics$4.05-1.2%$2.97$1.17▼$13.36$64.84M0.1822.87 million shs2.70 million shsCNTXContext Therapeutics$0.84-1.4%$0.76$0.49▼$2.59$75.35M1.9170,442 shs82,615 shsGNTAGenenta Science$3.93+3.3%$3.64$2.74▼$7.28$71.79M0.627,377 shs1,098 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos0.00%+7.30%+55.28%+21.02%+19.38%BTAIBioXcel Therapeutics0.00%-18.67%+195.62%+206.82%-58.84%CNTXContext Therapeutics0.00%-5.94%+18.31%+42.86%-65.85%GNTAGenenta Science0.00%+11.82%+5.34%-12.58%+1.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos1.3731 of 5 stars0.03.00.00.04.31.70.6BTAIBioXcel Therapeutics4.443 of 5 stars3.35.00.04.52.91.70.6CNTXContext Therapeutics3.6364 of 5 stars3.64.00.00.04.01.71.3GNTAGenenta Science2.2925 of 5 stars3.53.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ABTAIBioXcel Therapeutics 2.67Moderate Buy$39.75881.48% UpsideCNTXContext Therapeutics 3.17Buy$5.25525.00% UpsideGNTAGenenta Science 3.00Buy$25.00536.94% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, GNTA, CNTX, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/26/2025BTAIBioXcel TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025BTAIBioXcel TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.008/7/2025CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.008/7/2025CNTXContext TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/26/2025CNTXContext TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K890.06N/AN/A$5.51 per share0.69BTAIBioXcel Therapeutics$868K74.70N/AN/A($30.01) per share-0.13CNTXContext TherapeuticsN/AN/AN/AN/A$1.27 per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/4/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$12.64N/AN/AN/A-5,869.82%N/A-134.45%11/13/2025 (Estimated)CNTXContext Therapeutics-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)GNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/ALatest AIMD, GNTA, CNTX, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A8/12/2025Q2 2025BTAIBioXcel Therapeutics-$2.30-$2.45-$0.15-$2.45$0.21 million$0.12 million8/6/2025Q2 2025CNTXContext Therapeutics-$0.06-$0.09-$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61BTAIBioXcel TherapeuticsN/A0.760.74CNTXContext TherapeuticsN/A19.0919.09GNTAGenenta ScienceN/A6.896.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABTAIBioXcel Therapeutics30.68%CNTXContext Therapeutics14.03%GNTAGenenta Science15.13%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%BTAIBioXcel Therapeutics21.20%CNTXContext Therapeutics3.04%GNTAGenenta Science28.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.66 million4.17 millionNot OptionableBTAIBioXcel Therapeutics9016.01 million12.62 millionOptionableCNTXContext Therapeutics789.70 million86.98 millionNot OptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableAIMD, GNTA, CNTX, and BTAI HeadlinesRecent News About These CompaniesGenenta Science (NASDAQ:GNTA) Trading 7.4% Higher - Time to Buy?August 30 at 2:46 AM | marketbeat.comGenenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest UpdateAugust 7, 2025 | marketbeat.comAllianz SE Purchases 130,300 Shares of Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA)August 5, 2025 | marketbeat.comGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival SignalsJuly 1, 2025 | globenewswire.comGNTA Genenta Science S.p.A.May 30, 2025 | seekingalpha.comGenenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 8, 2025 | newsfilecorp.comNGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesMay 7, 2025 | globenewswire.comGenenta Showcases Strategic Vision at Premier Biotech Forum in QatarApril 15, 2025 | globenewswire.comGenenta Science announces EUR 20M financing to expand pipelineMarch 21, 2025 | markets.businessinsider.comGenenta Science Secures €20 Million Convertible Bond Financing for Oncology ResearchMarch 19, 2025 | tipranks.comGenenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival RatesMarch 19, 2025 | globenewswire.comIs Genenta Science S.p.A. (GNTA) the Best Italian Stock to Buy in 2025?February 13, 2025 | msn.comGenenta Science SpA ADRFebruary 1, 2025 | investing.comTOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 28, 2025 | prnewswire.comGenenta Science announces amendment to pact with AGC BiologicsJanuary 10, 2025 | finance.yahoo.comGenenta, AGC Biologics Strengthen Cell Therapy Manufacturing PactJanuary 9, 2025 | contractpharma.comCGenenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy ManufacturingJanuary 9, 2025 | globenewswire.comITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEJanuary 8, 2025 | prnewswire.comGenenta Science Enhances Manufacturing Agreement with AGC BiologicsJanuary 1, 2025 | markets.businessinsider.comGenenta Science Updates ATM Sales Agreement with New AgentDecember 20, 2024 | tipranks.comGenenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”October 23, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, GNTA, CNTX, and BTAI Company DescriptionsAinos NASDAQ:AIMD$3.82 -0.16 (-4.02%) As of 08/29/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioXcel Therapeutics NASDAQ:BTAI$4.05 -0.05 (-1.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.89 -0.16 (-4.05%) As of 08/29/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Context Therapeutics NASDAQ:CNTX$0.84 -0.01 (-1.20%) As of 08/29/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Genenta Science NASDAQ:GNTA$3.92 +0.13 (+3.29%) As of 08/29/2025 03:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
